Zivo Bioscience receives USDA CVB jurisdiction for coccidiosis biologic; new study in Sept 2022

Zivo Bioscience, Inc.

USDA CVB affirms jurisdiction over novel immune-modulating biologic for coccidiosis in broilers, removing regulatory ambiguity.
Company continues licensing discussions with a major animal health company for product candidate.
Strategic partner to begin 42-day in vivo study in September 2022; results expected Q1 2023.
No financial results or guidance were provided in this corporate update.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.